Biomarker For Sensitivity To Mtor Inhibitor Therapy In Kidney Cancer
|Document №||Publication date||Filed Date||Application №|
|9261498||February 16, 2016||March 17, 2006||11/886444|
The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregukted in pathologies such as cancer and to reagents and kits adapted for performing such methods. For example a correlation between VHL loss and mTOR inhibitor sensitivity in human kidney cancer cells is disclosed, indicating that VHL loss confers autonomous and angiogenic competitive advantages to such cells.